|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,799.40 INR | +0.83% |
|
+3.59% | +4.63% |
| Capitalization | 4,317B 46.98B 40.51B 36.56B 35.08B 63.98B 66.95B 432B 173B 2,070B 176B 173B 7,405B | P/E ratio 2026 * |
37x | P/E ratio 2027 * | 31.9x |
|---|---|---|---|---|---|
| Enterprise value | 4,093B 44.54B 38.4B 34.66B 33.26B 60.65B 63.48B 410B 164B 1,963B 167B 164B 7,020B | EV / Sales 2026 * |
7.05x | EV / Sales 2027 * | 6.22x |
| Free-Float |
44.9% | Yield 2026 * |
0.82% | Yield 2027 * | 0.92% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.83% | ||
| 1 week | +3.59% | ||
| Current month | +3.59% | ||
| 1 month | +6.15% | ||
| 3 months | -0.33% | ||
| 6 months | +12.91% | ||
| Current year | +4.63% |
| 1 week | 1,712 |  | 1,805.6 |
| 1 month | 1,693.4 | | 1,805.6 |
| Current year | 1,583.7 | | 1,806.6 |
| 1 year | 1,548 | | 1,851.2 |
| 3 years | 922.45 | | 1,960.35 |
| 5 years | 562.1 | | 1,960.35 |
| 10 years | 312 | | 1,960.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 2025-08-31 | |
| Director of Finance/CFO | 58 | 2025-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 73 | 2018-05-24 | |
| Director/Board Member | 70 | 2021-05-20 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.83% | +3.59% | +11.81% | +86.42% | 46.98B | |
| -1.08% | -6.07% | +35.47% | +149.13% | 33.69B | |
| -4.02% | -7.39% | +292.80% | +1,238.00% | 11.96B | |
| -0.39% | -2.00% | -9.41% | +49.98% | 11.61B | |
| -0.17% | -0.94% | +1.36% | +91.76% | 10B | |
| +5.59% | +3.46% | +71.48% | +46.60% | 8.21B | |
| -0.86% | -4.17% | +37.31% | +120.10% | 8.13B | |
| +1.12% | -5.74% | +53.86% | -11.04% | 7.52B | |
| +0.73% | -0.58% | +51.27% | +404.43% | 6.52B | |
| -1.54% | -3.77% | +10.48% | +52.79% | 6.2B | |
| Average | +0.02% | -1.96% | +55.64% | +222.82% | 15.08B | |
| Weighted average by Cap. | -0.06% | -1.33% | +45.43% | +196.49% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 581B 6.32B 5.45B 4.92B 4.72B 8.61B 9.01B 58.16B 23.3B 279B 23.72B 23.22B 996B | 644B 7.01B 6.04B 5.46B 5.24B 9.55B 9.99B 64.51B 25.84B 309B 26.31B 25.75B 1,105B |
| Net income | 116B 1.26B 1.09B 981M 941M 1.72B 1.8B 11.59B 4.64B 55.52B 4.73B 4.63B 199B | 136B 1.48B 1.27B 1.15B 1.1B 2.01B 2.11B 13.6B 5.45B 65.13B 5.55B 5.43B 233B |
| Net Debt | -224B -2.44B -2.1B -1.9B -1.82B -3.32B -3.48B -22.46B -9B -108B -9.16B -8.97B -385B | -312B -3.39B -2.93B -2.64B -2.53B -4.62B -4.84B -31.22B -12.51B -150B -12.73B -12.46B -535B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-03-06 | 1,799.40 ₹ | +0.83% | 3,669,921 |
| 26-03-05 | 1,784.50 ₹ | +1.94% | 3,600,895 |
| 26-03-04 | 1,750.50 ₹ | -0.11% | 4,914,857 |
| 26-03-02 | 1,752.50 ₹ | +0.89% | 3,919,270 |
| 26-02-27 | 1,737.00 ₹ | -2.73% | 3,041,489 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition